206 related articles for article (PubMed ID: 27130789)
1. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases.
Kim H; Gill B; Beriwal S; Huq MS; Roberts MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1175-83. PubMed ID: 27130789
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
Sher DJ; Wee JO; Punglia RS
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
[TBL] [Abstract][Full Text] [Related]
5. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
Lester-Coll NH; Dosoretz AP; Magnuson WJ; Laurans MS; Chiang VL; Yu JB
J Neurosurg; 2016 Dec; 125(Suppl 1):18-25. PubMed ID: 27903191
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC).
Donovan EK; Xie F; Louie AV; Chu W; Siva S; Kapoor A; Swaminath A
Clin Genitourin Cancer; 2022 Oct; 20(5):e353-e361. PubMed ID: 35490099
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
Cucchetti A; Piscaglia F; Cescon M; Colecchia A; Ercolani G; Bolondi L; Pinna AD
J Hepatol; 2013 Aug; 59(2):300-7. PubMed ID: 23603669
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Treatment Strategies for Spinal Metastases.
Kowalchuk RO; Mullikin TC; Kim DK; Morris JM; Ebner DK; Harmsen WS; Merrell KW; Beriwal S; Waddle MR; Kim H
Pract Radiat Oncol; 2022; 12(3):236-244. PubMed ID: 35045365
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Leung HW; Liu CF; Chan AL
Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases.
Lester-Coll NH; Rutter CE; Bledsoe TJ; Goldberg SB; Decker RH; Yu JB
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):663-72. PubMed ID: 27055395
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness Analysis of Stereotactic Radiosurgery Alone Versus Stereotactic Radiosurgery with Upfront Whole Brain Radiation Therapy for Brain Metastases.
Kim H; Rajagopalan MS; Beriwal S; Smith KJ
Clin Oncol (R Coll Radiol); 2017 Oct; 29(10):e157-e164. PubMed ID: 28552517
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis.
Gazelle GS; Hunink MG; Kuntz KM; McMahon PM; Halpern EF; Beinfeld M; Lester JS; Tanabe KK; Weinstein MC
Ann Surg; 2003 Apr; 237(4):544-55. PubMed ID: 12677152
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma.
Jin H; Chalkidou A; Hawkins M; Summers J; Eddy S; Peacock JL; Coker B; Kartha MR; Good J; Pennington M;
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e143-e154. PubMed ID: 32951952
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of External Beam Radiation Therapy versus Percutaneous Image-Guided Cryoablation for Palliation of Uncomplicated Bone Metastases.
Chang EM; Shaverdian N; Capiro N; Steinberg ML; Raldow AC
J Vasc Interv Radiol; 2020 Aug; 31(8):1221-1232. PubMed ID: 32674872
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare.
Parikh ND; Marshall VD; Green M; Lawrence TS; Razumilava N; Owen D; Singal AG; Feng M
J Med Imaging Radiat Oncol; 2018 Oct; 62(5):673-681. PubMed ID: 29877615
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis.
Helou J; Torres S; Musunuru HB; Raphael J; Cheung P; Vesprini D; Chung HT; D'Alimonte L; Krahn M; Morton G; Loblaw A
Clin Oncol (R Coll Radiol); 2017 Nov; 29(11):718-731. PubMed ID: 28916284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
